히알루론산 원료 시장 보고서 : 용도, 지역별(2024-2032년)

The global hyaluronic acid raw material market size reached US$ 7.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.8 Billion by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032.

Hyaluronic acid raw materials are the substances used for the manufacturing of the natural compound. The acid is naturally present in the eyes, hair, joints, nerves, cartilages and extracellular matrix in the skin. It can also be synthesized by fermenting wheat peptones, sugar and certain bacteria. These ingredients aid in supporting the functioning of the connective tissues and promoting collagen binding by building up the proteins and regulating water concentration in the skin. The topical application of the acid can assist in the regeneration of the skin and reduce inflammation. As a result, it finds extensive applications in the manufacturing of cosmetics, drug delivery systems, pharmaceuticals and nutritional supplements.

Hyaluronic Acid Raw Material Market Trends:

Significant growth in the pharmaceutical industry across the globe is of the key factors creating a positive outlook for the market. Hyaluronic acid acts as a viscoelastic and anti-surgical adhesion agent, which is widely used in ophthalmic, dermatological and orthopedic procedures as a mechanical barrier for tissue adherence. Moreover, the increasing demand for anti-wrinkle and anti-aging creams and solutions among the masses for cosmetic enhancements is providing a thrust to the market growth. Additionally, various technological advancements, such as the development of innovative solutions for targeted drug delivery and regenerative medicines, are acting as other growth-inducing factors. Healthcare providers are extensively using hyaluronic acid injections to provide lubrication, reduce inflammation and promote cartilage and bone growth in the joint. Other factors, including rising expenditure capacities of the consumers, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hyaluronic acid raw material market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on application.

Breakup by Application:

Ophthalmology

Cataract Surgery

Aqueous Eye Drop

Contact Lens

Orthopedics

Viscosupplements

Bone Regeneration

Dermatology

Intradermal

Dermal Filler

Wound Healing

Drug Delivery

Medical Device Coating

Surgical Adhesion Prevention

Biomaterials and Implants

Cell and Tissue Preservation

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Anika Therapeutics Inc., Contipro a.s., Galderma S.A., LG Chem Ltd., Lifecore Biomedical LLC (Landec Corporation), Sanofi S.A., Seikagaku Corporation, Smith & Nephew plc and Zimmer Biomet.

Key Questions Answered in This Report:

• How has the global hyaluronic acid raw material market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global hyaluronic acid raw material market?
• What are the key regional markets?
• What is the breakup of the market based on the application?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global hyaluronic acid raw material market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Hyaluronic Acid Raw Material Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Application

• 6.1 Ophthalmology
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Cataract Surgery
    • 6.1.2.2 Aqueous Eye Drop
    • 6.1.2.3 Contact Lens
  • 6.1.3 Market Forecast
• 6.2 Orthopedics
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Viscosupplements
    • 6.2.2.2 Bone Regeneration
  • 6.2.3 Market Forecast
• 6.3 Dermatology
  • 6.3.1 Market Trends
  • 6.3.2 Key Segments
    • 6.3.2.1 Intradermal
    • 6.3.2.2 Dermal Filler
    • 6.3.2.3 Wound Healing
  • 6.3.3 Market Forecast
• 6.4 Drug Delivery
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Medical Device Coating
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Surgical Adhesion Prevention
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Biomaterials and Implants
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast
• 6.8 Cell and Tissue Preservation
  • 6.8.1 Market Trends
  • 6.8.2 Market Forecast

7 Market Breakup by Region

• 7.1 North America
  • 7.1.1 United States
    • 7.1.1.1 Market Trends
    • 7.1.1.2 Market Forecast
  • 7.1.2 Canada
    • 7.1.2.1 Market Trends
    • 7.1.2.2 Market Forecast
• 7.2 Asia-Pacific
  • 7.2.1 China
    • 7.2.1.1 Market Trends
    • 7.2.1.2 Market Forecast
  • 7.2.2 Japan
    • 7.2.2.1 Market Trends
    • 7.2.2.2 Market Forecast
  • 7.2.3 India
    • 7.2.3.1 Market Trends
    • 7.2.3.2 Market Forecast
  • 7.2.4 South Korea
    • 7.2.4.1 Market Trends
    • 7.2.4.2 Market Forecast
  • 7.2.5 Australia
    • 7.2.5.1 Market Trends
    • 7.2.5.2 Market Forecast
  • 7.2.6 Indonesia
    • 7.2.6.1 Market Trends
    • 7.2.6.2 Market Forecast
  • 7.2.7 Others
    • 7.2.7.1 Market Trends
    • 7.2.7.2 Market Forecast
• 7.3 Europe
  • 7.3.1 Germany
    • 7.3.1.1 Market Trends
    • 7.3.1.2 Market Forecast
  • 7.3.2 France
    • 7.3.2.1 Market Trends
    • 7.3.2.2 Market Forecast
  • 7.3.3 United Kingdom
    • 7.3.3.1 Market Trends
    • 7.3.3.2 Market Forecast
  • 7.3.4 Italy
    • 7.3.4.1 Market Trends
    • 7.3.4.2 Market Forecast
  • 7.3.5 Spain
    • 7.3.5.1 Market Trends
    • 7.3.5.2 Market Forecast
  • 7.3.6 Russia
    • 7.3.6.1 Market Trends
    • 7.3.6.2 Market Forecast
  • 7.3.7 Others
    • 7.3.7.1 Market Trends
    • 7.3.7.2 Market Forecast
• 7.4 Latin America
  • 7.4.1 Brazil
    • 7.4.1.1 Market Trends
    • 7.4.1.2 Market Forecast
  • 7.4.2 Mexico
    • 7.4.2.1 Market Trends
    • 7.4.2.2 Market Forecast
  • 7.4.3 Others
    • 7.4.3.1 Market Trends
    • 7.4.3.2 Market Forecast
• 7.5 Middle East and Africa
  • 7.5.1 Market Trends
  • 7.5.2 Market Breakup by Country
  • 7.5.3 Market Forecast

8 SWOT Analysis

• 8.1 Overview
• 8.2 Strengths
• 8.3 Weaknesses
• 8.4 Opportunities
• 8.5 Threats

9 Value Chain Analysis

10 Porters Five Forces Analysis

• 10.1 Overview
• 10.2 Bargaining Power of Buyers
• 10.3 Bargaining Power of Suppliers
• 10.4 Degree of Competition
• 10.5 Threat of New Entrants
• 10.6 Threat of Substitutes

11 Price Analysis

12 Competitive Landscape

• 12.1 Market Structure
• 12.2 Key Players
• 12.3 Profiles of Key Players
  • 12.3.1 AbbVie Inc.
    • 12.3.1.1 Company Overview
    • 12.3.1.2 Product Portfolio
    • 12.3.1.3 Financials
    • 12.3.1.4 SWOT Analysis
  • 12.3.2 Anika Therapeutics Inc.
    • 12.3.2.1 Company Overview
    • 12.3.2.2 Product Portfolio
    • 12.3.2.3 Financials
    • 12.3.2.4 SWOT Analysis
  • 12.3.3 Contipro a.s.
    • 12.3.3.1 Company Overview
    • 12.3.3.2 Product Portfolio
  • 12.3.4 Galderma S.A.
    • 12.3.4.1 Company Overview
    • 12.3.4.2 Product Portfolio
  • 12.3.5 LG Chem Ltd.
    • 12.3.5.1 Company Overview
    • 12.3.5.2 Product Portfolio
    • 12.3.5.3 Financials
    • 12.3.5.4 SWOT Analysis
  • 12.3.6 Lifecore Biomedical LLC (Landec Corporation)
    • 12.3.6.1 Company Overview
    • 12.3.6.2 Product Portfolio
  • 12.3.7 Sanofi S.A.
    • 12.3.7.1 Company Overview
    • 12.3.7.2 Product Portfolio
    • 12.3.7.3 Financials
    • 12.3.7.4 SWOT Analysis
  • 12.3.8 Seikagaku Corporation
    • 12.3.8.1 Company Overview
    • 12.3.8.2 Product Portfolio
    • 12.3.8.3 Financials
  • 12.3.9 Smith & Nephew plc
    • 12.3.9.1 Company Overview
    • 12.3.9.2 Product Portfolio
    • 12.3.9.3 Financials
    • 12.3.9.4 SWOT Analysis
  • 12.3.10 Zimmer Biomet
    • 12.3.10.1 Company Overview
    • 12.3.10.2 Product Portfolio
    • 12.3.10.3 Financials